新辅助化疗后的间隔减瘤手术（IDS）是晚期卵巢癌的一种治疗选择。为了更好的生存需要最佳的手术；然而，虽然腹膜冲洗细胞学（PWC）已被确定为一个预后因素，但其在 IDS 期间的综合评估仍有待探索。因此，我们旨在通过回顾性审查 25 名接受过治疗的晚期卵巢癌患者的病历，评估 IDS 期间 PWC 的疗效，以及其他因素，包括残留病灶和模型癌症抗原 125 (CA-125) ELImination 速率常数 K (KELIM)。 2017年1月至2023年6月期间接受新辅助化疗和IDS。12例（48.0%）患者为PWC阳性，其余患者为PWC阴性。 PWC 在 IDS 期间进行剖腹手术，之后 5 名 (41.7%) PWC 阳性和 4 名 (30.8%) PWC 阴性患者接受贝伐单抗（一种抗血管内皮生长因子单克隆抗体）维持治疗。 4 名 (33.3%) PWC 阳性和 10 名 (76.9%) PWC 阴性患者接受了聚腺苷二磷酸 (ADP)-核糖聚合酶抑制剂治疗。在接受贝伐单抗和聚 ADP 核糖聚合酶抑制剂治疗的患者中，PWC 阳性和 PWC 阴性患者的总生存期和无进展生存期没有显着差异（分别为 p=0.27 和 0.20）。 CA-125 KELIM 有利和不利的患者之间的无进展生存期存在显着差异 (p = 0.02)。多变量分析表明，最佳手术和有利的 CA-125 KELIM 与更好的无进展生存期相关（分别为 p < 0.01 和 0.02），只有最佳手术才与更好的总生存期相关（p = 0.04）。IDS 时 PWC 呈阳性与晚期卵巢癌的生存无关。我们的研究结果表明，虽然 IDS 时的 PWC 状态应该是决定晚期卵巢癌患者生存的因素之一，但维持治疗的最新改进可能使 CA-125 KELIM 和 PWC 状态的组合成为选择治疗后更有用的预后因素。入侵检测系统。需要进一步研究来验证这些结果，强调 IDS 后维持治疗的潜在重要性，以及需要进一步研究来验证阳性 PWC 的临床意义。© 2024。作者。

Interval debulking surgery (IDS) following neoadjuvant chemotherapy is a treatment option for advanced ovarian cancer. Optimal surgery is required for better survival; however, while peritoneal washing cytology (PWC) has been identified as a prognostic factor, its comprehensive assessment during IDS remains unexplored. Therefore, we aimed to evaluate PWC efficacy during IDS, alongside other factors including residual disease and the modeled cancer antigen 125 (CA-125) ELIMination rate constant K (KELIM), by retrospectively reviewing the medical records of 25 patients with advanced ovarian cancer underwent neoadjuvant chemotherapy and IDS between January 2017 to June 2023.Twelve (48.0%) patients were PWC-positive, and the remainder were PWC-negative. PWC was performed at laparotomy during IDS, after which five (41.7%) PWC-positive and four (30.8%) PWC-negative patients received bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, for maintenance treatment. Four (33.3%) PWC-positive and 10 (76.9%) PWC-negative patients received poly adenosine diphosphate (ADP)-ribose polymerase inhibitors. In patients who received bevacizumab and poly ADP-ribose polymerase inhibitors, overall survival and progression-free survival did not significantly differ between those who were PWC-positive and PWC-negative (p = 0.27 and 0.20, respectively). Progression-free survival significantly differed between those with favorable and unfavorable CA-125 KELIM (p = 0.02). Multivariate analysis indicated that optimal surgery and favorable CA-125 KELIM were associated with better progression-free survival (p < 0.01 and 0.02, respectively), with only optimal surgery associated with better overall survival (p = 0.04).A positive PWC at IDS was not associated with survival in advanced ovarian cancer. Our findings indicate that although PWC status at IDS should be one of the factors determining survival in patients with advanced ovarian cancer, recent improvements in maintenance therapy may make the combination of CA-125 KELIM and PWC status a more useful prognostic factor in selecting treatment after IDS. Further studies are needed to validate these results, highlighting the potential importance of maintenance treatment after IDS and the need for further research to validate the clinical significance of a positive PWC.© 2024. The Author(s).